Imagine this: Your doctor prescribes a medicine that finally controls your chronic condition. A drug company offers a copay card to help cover your share—maybe knocking your monthly cost down to $5 or $0. Sounds great, right? But then your insurance plan pulls a switch: They say that help doesn't count toward your deductible or your yearly out-of-pocket maximum. Suddenly, you're on the hook for thousands once the card runs out—or even sooner.
This isn't a rare horror story. It's happening through programs called copay accumulators and copay maximizers, and it's hitting patients hard—especially those on expensive specialty drugs for conditions like rheumatoid arthritis, cancer, HIV, hepatitis, Crohn's, or cystic fibrosis.
These tricks let insurers capture money meant to help you, not them. Patients end up rationing meds, facing disease flares, or switching to less effective treatments—all while the insurance company benefits.
The NBPP is basically the government's annual "rulebook update" for Affordable Care Act (ACA) plans—like the individual and small-group markets on HealthCare.gov. It sets rules for what plans must cover, how much you pay out-of-pocket, and other protections.
In recent years:
A court case (HIV and Hepatitis Policy Institute v. HHS) struck down an older rule that let plans ignore most manufacturer help for cost-sharing. The court said: For most drugs (especially without a generic option), that help should count toward your deductible and out-of-pocket max. But enforcement has been on hold.
In October 2024, CMS (with HHS, Treasury, and Labor—the "Tri-agencies") released the NBPP for 2026 proposed rule. It didn't fix the big problems right away. Instead, it promised two future rule makings:
Until those future rules drop, plans can keep using accumulators and maximizers. That means continued risk of surprise high costs, skipped meds, and worse health outcomes for patients who rely on manufacturer help.
These delays highlight how policy moves slowly while patients face real hardship every month.
If you have employer coverage or use a specialty med with copay help, these programs could hit your wallet hard. They make "affordable" coverage feel anything but affordable. This is especially true when combined with other barriers like shifting costs or insurance denials (as our partners at the Patient Inclusion Council have shown in recent surveys).
Here's how to protect yourself:
True affordability means predictable costs and access to the meds that work for your body—not games that benefit insurers. We'll keep advocating so patient voices drive the fixes.
Have you run into accumulators or maximizers? Hit the share your story button and tell us all about it!